• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

2 Minute Medicine Rewind August 19 – August 25, 2013

bys25qthea
August 26, 2013
in Cardiology, Chronic Disease, Gastroenterology, Nephrology, Pulmonology, Weekly Rewinds
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

Image: PD 

In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week.

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease

Vedolizumab is a humanized monoclonal antibody targeting α4β7 integrin, which modulates gut lymphocyte trafficking and has shown efficacy for symptomatic relief in ulcerative colitis and Crohn’s disease in smaller phase II trials. Although similar in target to natalizumab (Tysabri), which antagonizes α4β1 and α4β7 integrin interactions to modulate CNS lymphocyte trafficking and has been used to treat MS, vedolizumab is reputed to have more gut specificity and avoid the limiting side effects of PML by JC polymoavirus reactivation. In these two phase 3 randomized, double blinded, placebo control trials, patients with active ulcerative colitis and Crohn’s disease were randomized to vedolizumab or placebo induction and maintenance therapy. In the ulcerative colitis induction trials, there was a statistically significant difference in clinical response (47.1% vs. 25.5%, p < 0.001) and a greater proportion of patients receiving vedolizumab had clinical remission (16.9% vs. 5.4%, p = 0.001). Similarly, for Crohn’s diease patients, there was a greater proportion of clinical remission at 6 weeks (14.5% vs. 6.8%, p = 0.02). For the ulcerative colitis maintenance trials, at one year there was a greater proportion of clinical remission in patients recieiving vedolizumab every 8 weeks and 4 weeks compared to placebo (41.8% vs. 44.8% vs. 15.9%, p < 0.001 for both comparisons). Results were similar for Crohn’s disease patients (39.0% for q8weeks, 36.4% for q4weeks, 21.6% for placebo, p < 0.001 and p = 0.004 respectively). No cases of PML were found in either study, however there were more serioud adverse events for Crohn’s disease patients receiving vedolizumab. Vedolimuzab potentially be an efficacious addition to the compendium of pharmacologic treatments for ulcerative colitis and Crohn’s disease. 

Association Between Urinary Albumin Excretion and Coronary Heart Disease in Black vs White Adults

Urinary albumin excretion has been associated with increased incident stroke risk and has more prevalent in black individuals than white individuals. In this prospective cohort study of US adults <35 years old, study participants (n = 28196) were stratified into patients with or without coronary heart disease and followed for a mean time of 4.4 years. The investigators found an almost 1.5x relative risk of incident CHD events in black participants with high urinary albumin-to-creatinine ratio (20.59 events per 1000 person-years) compared to white participants with high urinary albumin-to-creatinine ratio (13.60 events per 1000 person-years). For black participants, high urinary albumin-to-creatinine ratio was associated with greater risk of CHD events (HR comparing albumin-to-creatinine ratio of >300mg/g vs. <10mg/g, 3.21 [95% CI, 2.02-5.09]). Investigators concluded higher urinary albumin-to-creatinine ratio was associated with greater risk of incident but not recurrent CHD in black individuals when compared with white individuals. 

RELATED REPORTS

#VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension

Wellness Check: Exercise

Prevalence, awareness, treatment, and control of hypertension in China

Improved Blood Pressure Control Associated With a Large-Scale Hypertension Program

Kaiser Permanente Northern California (KPNC), an integrated health care delivery system, implemented a large scale hypertension program including a registry including more than 652,763 patients between 2001 and 2009, sharing of performance metrics, medical assistant visits for blood pressure measurement, and single-pill combination pharmacotherapy. In the time studied, there was an increase in the proportion of patients with good hypertension control from 43.6% in 2001 to 80.4% in 2009. This is greater compared to a comparison group from the National Commity for Quality Assurance quality measure reporting process (55.4% to 64.1% between 2006-2009 in California and 63.4% to 69.4% nationally). Investigators report the use of evidence based practice guidelines with algorithms, single pill combination therapy with lisinopril-HCTZ, and medical assistant follow-up measurements after medication changes as components of their comprehensive hypertension program which could have improved efficacy. 

Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease: A Cohort Study

Patients with chronic kidney disease disproportionally have hypertension compared to the general public. While there are specific blood pressure goals for diabetics and the general public, the ideal blood pressure for patients with CKD is unknown. In this study, investigators retrospectively looked at VA patients between 2005 and 2012 with a diagnosis of chronic kidney disease and looked for associations with all-cause mortality. Patients with systolic blood pressure between 130-159mmHg and diastolic blood pressure between 70-89mmHg at routine outpatient visits had lower mortaility rates than patients with SBP <130mmHg and DBP < 70mmHg. The results were consistent across subgroups of patients with or without proteinuria. There may not be advantage with aggressive blood pressure control in adults with CKD.

Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk

Recent months have identified a novel respiratory syndrome coronavirus (MERS-CoV) with possible human-to-human transmission by close direct contact. In this study, researcher’s modeled the infectivity of MERS-CoV based on WHO reports and published cased reports andestimate the basic reproductive number (R0, where a higher number suggest more transmitability) to be between 0.60 – 0.69, while the SARS-CoV R0 was 0.80. This suggests that there is low risk for pandemic potential, which is corroborated with case studies suggesting low infectivity.

By David Ouyang

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: CoronavirusCrohn's DiseasehypertensionMERS-CoVUlcerative Colitis
Previous Post

Antipsychotic users more likely to develop Type 2 Diabetes

Next Post

Stuttering associated with improved language and psychosocial functioning

RelatedReports

#VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
StudyGraphics

#VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension

February 3, 2023
Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Prevalence, awareness, treatment, and control of hypertension in China

January 20, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
Next Post
Clinical impression not reliable in identifying drug-seeking behavior

Stuttering associated with improved language and psychosocial functioning

Classics Series, Landmark Trials in Medicine

Prediction rules for children at low risk of clinically-important traumatic brain injury [Classics Series]

Smokeless tobacco use in children has not changed

USPTF recommends tobacco counseling for adolescents by primary care physicians

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options